Boehringer-Celebrate type 2 diabetes new drug Synjardy approved by the European Union June 09, 2015 Source: Mene The Boehringer Ingelheim-Lilly Diabetes Alliance has recently received good news on EU regulation. The Synthetic Synthetic Drug Synjardy (empagliflozin/Metformin Hydrochloride) has been approved by the European Commission for the development of type 2 diabetes (T2D) adults. Treatment of the patient. Synjardy is administered orally twice daily for 4 doses (empagliflozin/metformin): 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/850 mg, 12.5 mg/1000 mg. Synjardy is not intended for patients with type 1 diabetes and is not eligible for patients with diabetic ketoacidosis (increased ketone body in blood or urine). Synjardy is a compound monolith consisting of empagliflozin and metformin hydrochloride with two unique hypoglycemic mechanisms. Empagliflozin was approved by the European Union in 2014 under the trade name Jardiance, which is an emerging sodium-glucose cotransporter-2 (SGLT-2) inhibitor, while metformin hydrochloride is a common type 2 diabetes treatment. drug. SGLT-2 inhibitors have been shown to block glucose reabsorption in the kidneys, excreting excess glucose into the body, thereby reducing blood glucose levels, and the hypoglycemic effect is independent of beta cell function and insulin resistance. . Synjardy indications are combined with exercise and diet to improve glycemic control in adult patients with type 2 diabetes. Specifically, the European Commission has approved Synjardy for: (1) Type 2 diabetes patients who are still unable to adequately control their blood glucose levels at the maximum tolerated dose of metformin; (2) Metformin in combination with other hypoglycemic agents (including insulin) Type 2 diabetes patients who are unable to adequately control their blood glucose levels; (3) Type 2 diabetic patients undergoing a combination of empagliflozin and metformin. Synjardy's approval is based on strong clinical data from seven Phase III clinical trials investigating empagliflozin in combination with metformin monotherapy or in combination with other hypoglycemic agents (pioglitazone, sulfonylurea, DPP-4 inhibitor, insulin) Efficacy and safety during treatment. The data showed that empagliflozin (10 mg and 25 mg) combined with metformin resulted in a significant clinically significant reduction in blood glucose, body weight, and blood compared with metformin monotherapy when used with or without other hypoglycemic agents. In clinical trials, the most common side effect of Synjardy in combination with insulin and/or sulfonylureas is hypoglycemia. KOKEN Co., Ltd , https://www.hnb-maker.com